{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T18:22:01Z","timestamp":1777486921924,"version":"3.51.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-25510-6","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T12:31:26Z","timestamp":1763987486000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Mannitol versus furosemide for prevention of cisplatin-induced nephrotoxicity in a multicenter retrospective cohort study"],"prefix":"10.1038","volume":"15","author":[{"given":"Yudai","family":"Harimitsu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6183-4939","authenticated-orcid":false,"given":"Toshinobu","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mototsugu","family":"Shimokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanori","family":"Miyoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akari","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanobu","family":"Uchiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soichiro","family":"Ushio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chihiro","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Egawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"key":"25510_CR1","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1517\/14656566.4.6.889","volume":"4","author":"JT Hartmann","year":"2003","unstructured":"Hartmann, J. T. & Lipp, H. P. Toxicity of platinum compounds. Expert Opin. Pharmacother. 4, 889\u2013901 (2003).","journal-title":"Expert Opin. Pharmacother"},{"key":"25510_CR2","first-page":"4183","volume":"33","author":"KU Wensing","year":"2013","unstructured":"Wensing, K. U. & Ciarimboli, G. Saving ears and kidneys from cisplatin. Anticancer Res. 33, 4183\u20134188 (2013).","journal-title":"Anticancer Res."},{"key":"25510_CR3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1097\/MAJ.0b013e31812dfe1e","volume":"334","author":"X Yao","year":"2007","unstructured":"Yao, X., Panichpisal, K., Kurtzman, N. & Nugent, K. Cisplatin nephrotoxicity: A review. Am. J. Med. Sci. 334, 115\u2013124 (2007).","journal-title":"Am. J. Med. Sci."},{"key":"25510_CR4","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/sj.ki.5002786","volume":"73","author":"N Pabla","year":"2008","unstructured":"Pabla, N. & Dong, Z. Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies. Kidney Int. 73, 994\u20131007 (2008).","journal-title":"Kidney Int."},{"key":"25510_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s002800050618","volume":"40","author":"N Nagai","year":"1997","unstructured":"Nagai, N. & Ogata, H. Quantitative relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity in rats: Importance of area under the concentration-time curve (AUC) as the major toxicodynamic determinant in vivo. Cancer Chemother. Pharmacol. 40, 11\u201318 (1997).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"25510_CR6","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/clpt.2009.139","volume":"86","author":"KK Filipski","year":"2009","unstructured":"Filipski, K. K., Mathijssen, R. H., Mikkelsen, T. S., Schinkel, A. H. & Sparreboom, A. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin. Pharmacol. Ther. 86, 396\u2013402 (2009).","journal-title":"Clin. Pharmacol. Ther."},{"key":"25510_CR7","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1634\/theoncologist.2016-0319","volume":"22","author":"DJ Crona","year":"2017","unstructured":"Crona, D. J. et al. A systematic review of strategies to prevent cisplatin-induced nephrotoxicity. Oncologist 22, 609\u2013619 (2017).","journal-title":"Oncologist"},{"key":"25510_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF00686277","volume":"35","author":"V Pinzani","year":"1994","unstructured":"Pinzani, V. et al. Cisplatin-induced renal toxicity and toxicity-modulating strategies: A review. Cancer Chemother. Pharmacol. 35, 1\u20139 (1994).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"25510_CR9","first-page":"481","volume":"25","author":"Y Saito","year":"2017","unstructured":"Saito, Y. et al. Premedication with intravenous magnesium has a protective effect against cisplatin-induced nephrotoxicity. Support Care Cancer 25, 481\u2013487 (2017).","journal-title":"Support Care Cancer"},{"key":"25510_CR10","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1007\/s10147-020-01755-1","volume":"25","author":"T Hase","year":"2020","unstructured":"Hase, T. et al. Short hydration with 20 mEq of magnesium supplementation for lung cancer patients receiving cisplatin-based chemotherapy: A prospective study. Int. J. Clin. Oncol. 25, 1928\u20131935 (2020).","journal-title":"Int. J. Clin. Oncol."},{"key":"25510_CR11","first-page":"3345","volume":"30","author":"T Miyoshi","year":"2022","unstructured":"Miyoshi, T. et al. Preventive effect of 20 mEq and 8 mEq magnesium supplementation on cisplatin-induced nephrotoxicity: A propensity score\u2013matched analysis. Support Care Cancer 30, 3345\u20133351 (2022).","journal-title":"Support Care Cancer"},{"key":"25510_CR12","doi-asserted-by":"publisher","first-page":"10511","DOI":"10.1038\/s41598-024-61245-6","volume":"14","author":"A Takagi","year":"2024","unstructured":"Takagi, A. et al. Comparison of preventive effects of combined Furosemide and mannitol versus single diuretics, Furosemide or mannitol, on cisplatin-induced nephrotoxicity. Sci. Rep. 14, 10511 (2024).","journal-title":"Sci. Rep."},{"key":"25510_CR13","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1080\/01926230490508821","volume":"32","author":"AEM Vickers","year":"2004","unstructured":"Vickers, A. E. M. et al. Kidney slices of human and rat to characterize cisplatin-induced injury on cellular pathways and morphology. Toxicol. Pathol. 32, 577\u2013590 (2004).","journal-title":"Toxicol. Pathol."},{"key":"25510_CR14","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1007\/s10157-009-0215-1","volume":"13","author":"K Yokoo","year":"2009","unstructured":"Yokoo, K. et al. Enhanced renal accumulation of cisplatin via renal organic cation transporter deteriorates acute kidney injury in hypomagnesemic rats. Clin. Exp. Nephrol. 13, 578\u2013584 (2009).","journal-title":"Clin. Exp. Nephrol."},{"key":"25510_CR15","first-page":"2083","volume":"29","author":"AM B\u00e9gin","year":"2021","unstructured":"B\u00e9gin, A. M. et al. Effect of mannitol on acute kidney injury induced by cisplatin. Support Care Cancer 29, 2083\u20132091 (2021).","journal-title":"Support Care Cancer"},{"key":"25510_CR16","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/ajco.13423","volume":"17","author":"G Makimoto","year":"2021","unstructured":"Makimoto, G. et al. Randomized study comparing mannitol with Furosemide for the prevention of cisplatin-induced renal toxicity in non-small cell lung cancer: The OLCSG1406 trial. Asia Pac. J. Clin. Oncol. 17, 101\u2013108 (2021).","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"25510_CR17","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1007\/s11096-018-0677-x","volume":"40","author":"M El Hamamsy","year":"2018","unstructured":"El Hamamsy, M., Kamal, N., Bazan, N. S. & El Haddad, M. Evaluation of the effect of Acetazolamide versus mannitol on cisplatin-induced nephrotoxicity, a pilot study. Int. J. Clin. Pharm. 40, 1539\u20131547 (2018).","journal-title":"Int. J. Clin. Pharm."},{"key":"25510_CR18","doi-asserted-by":"publisher","first-page":"e6839","DOI":"10.1002\/cam4.6839","volume":"13","author":"E Murakami","year":"2024","unstructured":"Murakami, E. et al. Mannitol versus Furosemide in patients with thoracic malignancies who received cisplatin-based chemotherapy using short hydration: A randomized phase II trial. Cancer Med. 13, e6839 (2024).","journal-title":"Cancer Med."},{"key":"25510_CR19","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/jcpt.12509","volume":"42","author":"CM Mach","year":"2017","unstructured":"Mach, C. M. et al. A retrospective evaluation of Furosemide and mannitol for prevention of cisplatin-induced nephrotoxicity. J. Clin. Pharm. Ther. 42, 286\u2013291 (2017).","journal-title":"J. Clin. Pharm. Ther."},{"key":"25510_CR20","first-page":"73","volume":"65","author":"S Ostrow","year":"1981","unstructured":"Ostrow, S. et al. High-dose cisplatin therapy using mannitol versus furosemide diuresis: Comparative pharmacokinetics and toxicity. Cancer Treat. Rep. 65, 73\u201378 (1981).","journal-title":"Cancer Treat. Rep."},{"key":"25510_CR21","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1159\/000510384","volume":"99","author":"T Miyoshi","year":"2021","unstructured":"Miyoshi, T. et al. Cisplatin-Induced nephrotoxicity: A multicenter retrospective study. Oncology 99, 105\u2013113 (2021).","journal-title":"Oncology"},{"key":"25510_CR22","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1200\/JCO.2017.75.7161","volume":"36","author":"SS Motwani","year":"2018","unstructured":"Motwani, S. S. et al. Development and validation of a risk prediction model for acute kidney injury after the first course of cisplatin. J. Clin. Oncol. 36, 682\u2013688 (2018).","journal-title":"J. Clin. Oncol."},{"key":"25510_CR23","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1159\/000356587","volume":"85","author":"T Mizuno","year":"2013","unstructured":"Mizuno, T. et al. The risk factors of severe acute kidney injury induced by cisplatin. Oncology 85, 364\u2013369 (2013).","journal-title":"Oncology"},{"key":"25510_CR24","doi-asserted-by":"publisher","first-page":"e101902","DOI":"10.1371\/journal.pone.0101902","volume":"9","author":"Y Kidera","year":"2014","unstructured":"Kidera, Y. et al. Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection. PLOS One 9, e101902 (2014).","journal-title":"PLOS One"},{"key":"25510_CR25","doi-asserted-by":"publisher","first-page":"17126","DOI":"10.1038\/s41598-023-44477-w","volume":"13","author":"Y Saito","year":"2023","unstructured":"Saito, Y. et al. Risk factor analysis for cisplatin-induced nephrotoxicity with the short hydration method in diabetic patients. Sci. Rep. 13, 17126 (2023).","journal-title":"Sci. Rep."},{"key":"25510_CR26","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.3390\/toxins2112490","volume":"2","author":"RP Miller","year":"2010","unstructured":"Miller, R. P., Tadagavadi, R. K., Ramesh, G. & Reeves, W. B. Mechanisms of cisplatin nephrotoxicity. Toxins 2, 2490\u20132518 (2010).","journal-title":"Toxins"},{"key":"25510_CR27","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1093\/jjco\/hyu004","volume":"44","author":"T Yoshida","year":"2014","unstructured":"Yoshida, T. et al. Protective effect of magnesium preloading on cisplatin-induced nephrotoxicity: A retrospective study. Jpn. J. Clin. Oncol. 44, 346\u2013354 (2014).","journal-title":"Jpn J. Clin. Oncol."},{"key":"25510_CR28","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/j.jacc.2008.07.051","volume":"52","author":"C Ronco","year":"2008","unstructured":"Ronco, C. et al. Cardiorenal syndrome. J. Am. Coll. Cardiol. 52, 1527\u20131539 (2008).","journal-title":"J. Am. Coll. Cardiol."},{"key":"25510_CR29","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00280-003-0620-1","volume":"52","author":"JT Santoso","year":"2003","unstructured":"Santoso, J. T., Lucci, J. A., Coleman, R. L., Schafer, I. & Hannigan, E. V. Saline, mannitol, and Furosemide hydration in acute cisplatin nephrotoxicity: A randomized trial. Cancer Chemother. Pharmacol. 52, 13\u201318 (2003).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"25510_CR30","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/1440-1681.12031","volume":"40","author":"RG Evans","year":"2013","unstructured":"Evans, R. G. et al. Haemodynamic influences on kidney oxygenation: clinical implications of integrative physiology. Clin. Exp. Pharmacol. Physiol. 40, 106\u2013122 (2013).","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"25510_CR31","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrc2167","volume":"7","author":"L Kelland","year":"2007","unstructured":"Kelland, L. The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer 7, 573\u2013584 (2007).","journal-title":"Nat. Rev. Cancer"},{"key":"25510_CR32","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.2353\/ajpath.2010.090610","volume":"176","author":"G Ciarimboli","year":"2010","unstructured":"Ciarimboli, G. et al. Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. Am. J. Pathol. 176, 1169\u20131180 (2010).","journal-title":"Am. J. Pathol."},{"key":"25510_CR33","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1038\/ki.1997.409","volume":"52","author":"OS Better","year":"1997","unstructured":"Better, O. S. et al. Mannitol therapy revisited (1940\u20131997). Kidney Int. 52, 886\u2013894 (1997).","journal-title":"Kidney Int."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25510-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25510-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25510-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T12:31:27Z","timestamp":1763987487000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25510-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["25510"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-25510-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6773221\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"29 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All procedures performed in studies involving human participants were conducted in accordance with the ethical standards of the institutional research committee and the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}],"article-number":"41537"}}